Mecobalamin, a naturally occurring form of vitamin B12, was approved in Japan on September 24 under the brand name Rozebalamin to treat ALS.Vitamin B Injections prove to be helpful for newly diagnosed ALS patients
The therapy, which will be manufactured and marketed by Eisai, is intended to slow functional decline in people with the disease.
The approval was based on data from a Phase 3 clinical trial called JETALS (NCT03548311), in which Rozebalamin slowed ALS disease progression when given alone or in combination with standard ALS treatments.
“Eisai is committed to further addressing the diverse needs of, and increasing the benefits of, patients and their families by providing Rozebalamin as a new treatment option for ALS patients,” the company said in a press release.
Mecobalamin is highly sensitive to light, which can cause it to become chemically unstable. The company created a vial that offers a high level of light protection, with a resealable window on the neck that allows healthcare providers to easily see the medication during dilution and withdrawal.
Augie’s Quest to Cure ALS provides this information based on public information and recommends you speak to your neurologist to determine if this is a helpful option for you.
Join our Quest
Would you like to be notified of new resources when they are published? Please sign up here!
